The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland.

Judith Everts-GraberMathias WengerSven OserUeli StuderChristian SteinerHans-Rudolf ZiswilerKaroline SromekGernot SchmidBrigitta GahlHansJörg HäuselmannStephan ReichenbachThomas Lehmann

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2024)

Prior antiresorptive therapy blunted the BMD response to romosozumab, and the duration was correlated with BMD changes at both the lumbar spine and total hip.

Keyphrases

bone mineral density
total hip
postmenopausal women
total knee arthroplasty
body composition
randomized controlled trial
cross sectional
double blind
mesenchymal stem cells
replacement therapy
combination therapy
cell therapy